As antibody based drugs have several advantages including safety, efficacy and high specificity, they have become the preferred therapeutics. Fully native human mAbs hold the most promising potentials for safety and efficacy issues of drug development in clinical trials. For many years, immunologists have been trying to take advantage of native antibodies for therapeutic uses, thus MBC established a platform technology with highly efficient immortalization of human primary B cells. Moreover, MBC also sets up a standard operation process to facilitate production of human native Abs by integration of a robotic system for B cell cloning and a high throughput screening system for antibody with neutralizing activity in micro-volume. Therefore, we expect to generate more human native mAbs for therapeutic applications regarding infectious diseases in the future.

Illustration of Medigen’s platform technology 01-04